Cromoglicate sodium - topical
Classification: BATC code: R01AC01, S01GX01
Summary
Published controlled studies on differences between men and women regarding pharmacokinetics, dosing and safety of sodium cromoglycate are lacking. The effect of sodium cromoglycate as a treatment for improving tear film break up time was in a small study shown to be better in women.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
Additional information
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of sodium cromoglycate have been found.
Effects
In a randomized study of sodium cromoglycate’s prolonging effect of tear film break up time in patients with an [abnormal tear film break-up] acute tear film break up phenomenon (13 men, 28 women) men had a lower increase in mean tear film break up time than women (39% vs 83%) [1]. Women have been shown to have a higher concentration of magnesium ions in their tear fluid [2]. A hypothesis to explain the better effect is that magnesium ions in tear fluid induce gelling of sodium cromoglycate thus creating a protective film [1].
Adverse effects
No studies with a clinically relevant sex analysis regarding the adverse effects of sodium cromoglycate have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Updated: 2019-02-26
Date of litterature search: 2015-10-21
References
- Felius K, van Bijsterveld OP. Effect of sodium cromoglycate on tear film break-up time. Ann Ophthalmol. 1984;16:80-2. PubMed
- Frauch P. [Lacrimal gland secretion and precorneal film in healthy humans]. Pharm Acta Helv. 1978;53:1-16. PubMed
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk
- Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.] länk
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson